ADI-PEG in Patients With Metastatic Melanoma
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This is a study to determine the safety and toxicity of increasing doses of arginine deiminase combined to polyethylene glycol (ADI-PEG) in patients with nonresectable metastatic melanoma.
| Condition | Intervention | Phase |
|---|---|---|
|
Melanoma Neoplasm Metastasis |
Drug: ADI PEG |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Phase I Testing of ADI-PEG in Metastatic Melanoma |
| Estimated Enrollment: | 15 |
| Study Start Date: | September 2001 |
| Estimated Study Completion Date: | August 2003 |
The use of amino acid degrading enzymes derived from microbial sources has proven to be an effective means of controlling some forms of cancer auxotrophic for nonessential amino acids. Recently it has been shown that human melanomas are auxotrophic for arginine. As arginine is a nonessential amino acid for humans, elimination of it may prove to be an effective method for controlling cancer. Laboratory studies have provided promising results with the arginine-degrading enzyme arginine deiminase (ADI) coupled to polyethylene glycol (PEG) to enhance its circulating half-life.
In this study, patients each receive 3 intramuscular treatments of ADI-SS PEG over a 4-week period. There are 4 cohorts of patients each receiving a different dose level. Pharmacokinetics, pharmacodynamics, safety and toxicity, and immunogenicity studies will be performed.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion criteria:
- Histologically confirmed metastatic melanoma
- Nonresectable disease
- Measurable or evaluable disease
- Progressive disease following standard chemotherapy, radiotherapy, surgery, or immunotherapy; and no longer responding to therapy
- Recovered from prior surgery
- Karnofsky performance status 70 or higher
- Expected survival of at least 12 weeks
- Bilirubin less than 2.0 mg/dL
- Albumin greater than 3.0 g/dL
- SGOT less than 5 times upper limit of normal (ULN)
- Alkaline phosphatase less than 5 times ULN
- Ammonia less than 55 microg/dL
- Glucose greater than 60 mg/dL
- Amylase less than 1.5 times ULN
- Absolute neutrophil count greater than 1,500/mm3
- Platelet count greater than 100,000/mm3
- Patients must use 2 forms of effective contraception
Exclusion criteria:
- Prior therapy within the past 4 weeks
- Ascites or pleural effusion
- Significant cardiac disease (i.e., New York Heart Association class III or IV heart disease)
- Pregnant or nursing
- Concurrent enrollment in another IND study
- Serious infection requiring antibiotics
Contacts and Locations More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00029900 History of Changes |
| Other Study ID Numbers: | FD-R-2003-01, FD-R-002003-01 |
| Study First Received: | January 24, 2002 |
| Last Updated: | January 31, 2006 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by FDA Office of Orphan Products Development:
|
Dose-Response Relationship, Drug Polyethylene Glycol Arginine Deiminase |
Additional relevant MeSH terms:
|
Neoplasms Melanoma Neoplasm Metastasis Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal |
Neoplasms by Histologic Type Neoplasms, Nerve Tissue Nevi and Melanomas Neoplastic Processes Pathologic Processes |
ClinicalTrials.gov processed this record on May 19, 2013